127113-13-7

Basic information

• Product Name: (+/-)-2-amino-N-{3-(2-chlorobenzoyl)-5-[2-(4-isobutylphenyl)ethyl]-2-thienyl}propionamide
• CAS NO: 127113-13-7
• Molecular Weight: 469.047
• Mol File: 127113-13-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (+/-)-2-amino-N-{3-(2-chlorobenzoyl)-5-[2-(4-isobutylphenyl)ethyl]-2-thienyl}propionamide(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-2-amino-N-{3-(2-chlorobenzoyl)-5-[2-(4-isobutylphenyl)ethyl]-2-thienyl}propionamide(127113-13-7)
• EPA Substance Registry System: (+/-)-2-amino-N-{3-(2-chlorobenzoyl)-5-[2-(4-isobutylphenyl)ethyl]-2-thienyl}propionamide(127113-13-7)

Safety Data

• Hazardous Substances Data: 127113-13-7(Hazardous Substances Data)

Usage

Description

(+/-)-2-amino-N-3-(2-chlorobenzoyl)-5-[2-(4-isobutylphenyl)ethyl]-2-thienylpropionamide is a synthetic organic molecule belonging to the class of thienylpropionamides. It features an amino group, a thienyl ring, and benzoyl and isobutylphenyl substituents, which may contribute to its potential pharmaceutical applications in medicinal chemistry and drug development.
Used in Pharmaceutical Industry:
(+/-)-2-amino-N-3-(2-chlorobenzoyl)-5-[2-(4-isobutylphenyl)ethyl]-2-thienylpropionamide is used as a potential therapeutic agent for the treatment of certain diseases or conditions due to its unique molecular structure and possible biological activity. Further research and evaluation of its pharmacological properties are required to fully understand its potential therapeutic benefits.

Upstream product

• 117280-04-3 2-amino-3-(2-chlorobenzoyl)-5-(2-(4-isobutylphenyl)ethyl)thiophene 
• 1041514-31-1 4-(4'-s-butylphenyl)butanoic acid 
• 117280-05-4 4-(4-isobutylphenyl)butyraldehyde 
• 147598-20-7 4-(4-Isobutyl-phenyl)-butan-1-ol 
• 73120-67-9 4-(4-isobutylphenyl)-4-oxobutanoic acid 
• 538-93-2 1-phenyl-2-methylpropane 
• 127113-12-6 (+/-)-N-{3-(2-chlorobenzoyl)-5-[2-(4-isobutylphenyl)ethyl]-2-thienyl}-2-phthalimidopropanamide 

Downstream Products

• 117279-73-9 4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 
• 117280-39-4 5-(2-Chloro-phenyl)-7-[2-(4-isobutyl-phenyl)-ethyl]-3-methyl-1,3-dihydro-thieno[2,3-e][1,4]diazepine-2-thione 
• 117280-40-7 [5-(2-Chloro-phenyl)-7-[2-(4-isobutyl-phenyl)-ethyl]-3-methyl-1,3-dihydro-thieno[2,3-e][1,4]diazepin-(2Z)-ylidene]-hydrazine 
• 117280-38-3 5-(2-Chloro-phenyl)-7-[2-(4-isobutyl-phenyl)-ethyl]-3-methyl-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 

Relevant articles and documents

Structural optimization of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines as antagonists for platelet activating factor: Pharmacological contribution of substituents at the 2- and 6-positions of a condensed ring system

A series of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives bearing substituents at the 2- and 6-positions were synthesized, and evaluated in vitro for their inhibitory activity on rabbit platelet aggregation induced by platelet activating factor (PAF) and in vivo for their preventing effect on PAF-induced mortality in mice. The length of alkyl or arylalkyl side chain at the 2-position was responsible for enhancing the affinity for the PAF receptor. The simultaneous substitution at both the 2- and 6-positions resulted in a successful separation of the affinity for the PAF receptor from that for the benzodiazepine (BZ) receptor. Thus, (±)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]- 6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine (Y-24180) was confirmed to be a specific antagonist for the PAF receptor and is currently under clinical trials.